

REGIOSPECIFIC SYNTHESIS OF 11-DESOXYANTHRACYCLINE ANTIBIOTICS STARTING WITH ALOE-EMODIN

J. Alexander, D. L. Flynn, L. A. Mitscher\* and T. Veysoglu  
Department of Medicinal Chemistry, The University of Kansas  
Lawrence, Kansas 66045

ABSTRACT: The regiospecific synthesis of an established 11-desoxyanthracycline synthon (8b) from aloe-emodin (3a) is described.

The contemporary search for analogues of the anthracycline antitumor antibiotics daunomycin<sup>1</sup> and doxorubicin<sup>2</sup> is intense. Particularly desired is the development of analogues retaining antitumor activity but with reduced cardiotoxicity.<sup>3</sup> Toward this end, we consider the 11-desoxyanthracyclines as an attractive area for synthetic exploration. Recently, the isolation and antitumor activities of aclacinomycin A (1a),<sup>4</sup> and 11-desoxydaunomycin (2a),<sup>5</sup> as well as 11-desoxydoxorubicin (2b)<sup>5</sup> have been reported. Although much synthetic effort has been directed toward daunomycinone, none of these procedures appear applicable to the regiospecific synthesis of 11-desoxyanthracyclinones 1b, 2c, or 2d.<sup>6,7</sup>

Recent communications describing the synthesis of the 11-desoxydaunomycinone synthon 8b,<sup>8,9</sup> have prompted us to report our quite different approach. Our work is based upon the convenient availability of the naturally-occurring anthraquinone, aloe-emodin (3a).<sup>10</sup> O-Allylation (3c) and Claisen rearrangement (4a) proceed from known ether 3b<sup>10</sup> in 66 and 96% yields.<sup>11</sup> Peracetylation (4b, pyridine/Ac<sub>2</sub>O; 98%) followed by hydroboration (BH<sub>3</sub>/THF; H<sub>2</sub>O<sub>2</sub>/NaOAc; 42%) gave the desired primary alcohol (5a). Oxidation (CrO<sub>3</sub>/H<sub>2</sub>SO<sub>4</sub>/Me<sub>2</sub>CO) and esterification/ethanolysis (EtOH/cat. H<sub>2</sub>SO<sub>4</sub>) completed elaboration of the lower side chain in the form of ester 5b (64% from 5a): mp 155-158°C; IR (KBr): 1730 cm<sup>-1</sup>, 1668, 1626, 1584; PMR (CDCl<sub>3</sub>): 1.14δ (3H, t, J=7 Hz, -OCH<sub>2</sub>CH<sub>3</sub>), 1.62 (1H, s, -OH), 2.66-3.30 (4H, m, ArCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Et), 4.10 (3H, s, ArOCH<sub>3</sub>), 4.12 (2H, q, J=7 Hz, -OCH<sub>2</sub>CH<sub>3</sub>), 4.86 (2H, d (broad), J=6 Hz, -CH<sub>2</sub>OH), 7.40-8.04 (4H, m, ArH-4,5-7), 13.16 (1H, s, ArOH); e.i.m.s. 384 (M<sup>+</sup>); λ<sub>MeOH</sub><sup>max</sup> 228 nm (ε 37450), 258 (24575), 418 (10650). Attempts at direct introduction of this side chain via a Marschalk-type sequence were considerably less successful.

After numerous failures with various sequences, homologation/elaboration of the original benzylic alcohol moiety was achieved by oxidation of 5b (pcc/CH<sub>2</sub>Cl<sub>2</sub>; 89%) to aldehyde 6a followed by olefination (6b; 83%) with methoxymethyltriphenylphosphorane (n-BuLi/DMSO).

Hydrolysis to homologated aldehyde 7a proceeded cleanly but isolation was complicated by dimerization/polymerization. Thus, 6b was more conveniently hydrolyzed ( $\text{Me}_2\text{CO}/\text{H}_2\text{O}/\text{H}_2\text{SO}_4$ ) to 7a and this was oxidized *in situ* ( $\text{CrO}_3/\text{H}_2\text{SO}_4$ ) to 7b. Without further purification, 7b was esterified ( $\text{MeOH}/\text{H}_2\text{SO}_4$ ) to give diester 7c in 83% overall yield from 6b: mp 167.5-169°C; IR (KBr): 1732  $\text{cm}^{-1}$ , 1670, 1628, 1588; PMR ( $\text{CDCl}_3$ ): 2.44-2.72 $\delta$  (2H, m,  $\text{ArCH}_2\text{CH}_2\text{CO}_2\text{Me}$ ), 2.84-3.12 (2H, m,  $\text{ArCH}_2\text{CH}_2\text{CO}_2\text{Me}$ ), 3.55 (3H, s,  $\text{CO}_2\text{CH}_3$ ), 3.60 (3H, s,  $\text{CO}_2\text{CH}_3$ ), 3.74 (2H, s,  $\text{ArCH}_2\text{CO}_2\text{Me}$ ), 3.94 (3H, s,  $\text{ArOCH}_3$ ), 7.12-7.90 (4H, m,  $\text{ArH-4,5-7}$ ), 13.06 (1H, s,  $\text{ArOH}$ ); e.i.m.s. 412 ( $\text{M}^+$ );  $\lambda_{\text{MeOH}}^{\text{max}}$  228 nm ( $\epsilon$  38450), 259 (23950), 417 (10400).

Dieckmann cyclization of 7c ( $t\text{-BuOK}/\text{DMSO}$ ) afforded keto ester 8a in 88% yield. Hydrolysis/decarboxylation ( $\text{AcOH}/\text{H}_2\text{O}/\text{H}_2\text{SO}_4$ ) afforded the desired 11-desoxydaunomycinone precursor (8b) in 76% isolated yield: dp 241-243°C; IR (KBr): 1702  $\text{cm}^{-1}$ , 1668, 1624, 1580; PMR ( $\text{CDCl}_3$ ): 2.62 $\delta$  (2H, t,  $J=7$  Hz,  $\text{ArCH}_2\text{CH}_2\text{CO-}$ ), 3.27 (2H, t,  $J=7$  Hz,  $\text{ArCH}_2\text{CH}_2\text{CO-}$ ), 3.71 (2H, s,  $\text{ArCH}_2\text{CO-}$ ), 4.11 (3H, s,  $\text{OCH}_3$ ), 7.40 (1H, d, d,  $J=8.0, 1.5$  Hz,  $\text{ArH-3}$ ), 7.58 (1H, s,  $\text{ArH-11}$ ), 7.77 (1H, t,  $J=8.0$  Hz,  $\text{ArH-2}$ ), 8.00 (1H, d, d,  $J=8.0, 1.5$  Hz,  $\text{ArH-1}$ ) and 14.27 (1H, s,  $\text{ArOH}$ ); e.i.m.s. 322 ( $\text{M}^+$ );  $\lambda_{\text{MeOH}}^{\text{max}}$  225 nm ( $\epsilon$  29425), 259 (22950) and 416 (9550).


Since methods exist for the elaboration of the requisite side chain at C-9 and hydroxylation at C-7 of 8c,<sup>12a-d</sup> it has been suggested that similar transformation of 8b into the aglycones 2c or 2d should be straightforward.<sup>8</sup> Coupling of these aglycones with L-daunosamine by known methodology<sup>12d,e, 13</sup> would complete the synthetic preparation of 11-desoxydaunomycin (2a) and 11-desoxydoxorubicin (2b).

Acknowledgment: The authors thank ADRIA Laboratories for financial support of this work and Drs. H. J. Eichel, J. H. Short and D. Lednicer for encouragement and stimulating discussions.

#### References


1. F. Arcamone, G. Franceschi, P. Orezzi, G. Cassinelli, W. Barbieri and R. Mondelli, *J. Am. Chem. Soc.*, **86**, 5334 (1964).
2. F. Arcamone, G. Franceschi, S. Penco and A. Silva, *Tetrahedron Lett.*, 1007 (1969).
3. a) R. H. Blum and S. K. Carter, *Ann. Intern. Med.*, **82**, 249 (1974); (b) E. A. Lefrak, J. Pitha, S. Rosenheim and J. A. Gottlieb, *Cancer*, **32**, 302 (1973); (c) L. Lenaz and J. A. Page, *Cancer Treat. Rev.*, **3**, 111 (1976).
4. a) T. Oki, Y. Matsuzawa, A. Yoshimoto, K. Numata, I. Kitamura, S. Hori, A. Takamatsu, H. Umezawa, M. Ishizuka, H. Naganawa, H. Suda, M. Hamada and T. Takeuchi, *J. Antibiotics*, **28**, 830 (1975); (b) T. Oki, N. Shibamoto, Y. Matsuzawa, T. Ogasawara, A. Yoshimoto, I. Kitamura, T. Inui, H. Naganawa, T. Takeuchi and H. Umezawa, *J. Antibiotics*, **30**, 683 (1977); (c) T. W. Doyle, D. E. Nettleton, R. E. Grulich, D. M. Balitz, D. L. Johnson and A. L. Vulcano, *J. Am. Chem. Soc.*, **101**, 7041 (1979).
5. a) F. Arcamone, G. Cassinelli, F. DiMatteo, S. Forenza, M. C. Ripamonti, G. Rivola and A. Vigevani, *J. Am. Chem. Soc.*, **102**, 1462 (1980); (b) G. Cassinelli, F. DiMatteo, S. Forenza, M. C. Ripamonti, G. Rivola, F. Arcamone, A. DiMarco, A. M. Casazza, C. Soranzo and G. Pratesi, *J. Antibiotics*, **33**, 1468 (1980).
6. For a comprehensive review on recent syntheses of daunomycinone, see T. R. Kelly, *Annu. Repts. in Med. Chem.*, **14**, 288 (1979).

7. Some approaches to a regiospecific solution to this problem have appeared in abstract form: A. S. Kende, J. P. Rizzi and S. D. Boettger, Abstr. Second Chem. Congr. North Amer. Continent, San Francisco, Orgn., 20 (1980); T. Li and T. C. Walsgrove, ibid., Orgn., 23 (1980).
8. J. G. Bauman, R. B. Barber, R. D. Gleiss and H. Rapoport, Tetrahedron Lett., 4777 (1980).
9. J. P. Gesson, J. C. Jacquesy and M. Mondon, Tetrahedron Lett., 3351 (1980).
10. For previous work from this laboratory based upon aloe-emodin, see:  
 a) J. Alexander, A. V. Bhatia, L. A. Mitscher, S. Omoto and T. Suzuki, J. Org. Chem., 45, 20 (1980); (b) J. Alexander, A. V. Bhatia, G. W. Clark, III, A. Leutzow, L. A. Mitscher, S. Omoto and T. Suzuki, J. Org. Chem., 45, 24 (1980).
11. All new compounds gave appropriate microanalyses and spectra, including unit resolution e.i.m.s.
12. a) C. M. Wong, R. Schwenk, D. Popien and T.-L. Ho, Can. J. Chem., 51, 466 (1973); (b) R. C. Larock, J. Org. Chem., 39, 3721 (1974); (c) A. S. Kende, Y.-G. Tsay and J. E. Mills, J. Am. Chem. Soc., 98, 1967 (1976); (d) T. H. Smith, A. N. Fujiwara, W. W. Lee and D. W. Henry, J. Am. Chem. Soc., 98, 1969 (1976); (e) T. H. Smith, A. N. Fujiwara, W. W. Lee, H. Y. Wu and D. W. Henry, J. Org. Chem., 42, 3653 (1977).
13. F. Arcanone, Lloydia, 40, 45 (1977).



1a, R=L-Daunosamine

1b, R=H




2a, R=L-Daunosamine, X=H

2b, R=L-Duanosamine, X=OH

2c, R=X=H


2d, R=H, X=OH



3a, R=R'=H

3b, R=CH<sub>3</sub>, R'=H

3c, R=CH<sub>3</sub>, R'=CH<sub>2</sub>CH=CH<sub>2</sub>




4a, R=X=H, R'=CH<sub>2</sub>CH=CH<sub>2</sub>

4b, R=X=Ac, R'=CH<sub>2</sub>CH=CH<sub>2</sub>


5a, R=X=Ac, R'=(CH<sub>2</sub>)<sub>3</sub>OH

5b, R=X=H, R'=(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Et



6a, X=O


6b, X=CHOCH<sub>3</sub>



7a, R=H, R'=Et

7b, R=OH, R'=H

7c, R=OCH<sub>3</sub>, R'=CH<sub>3</sub>



8a, R=CO<sub>2</sub>CH<sub>3</sub>, R'=H

8b, R=R'=H

8c, R=H, R'=OH

(Received in USA 26 May 1981)